ARTICLE | Company News
Lilly pairs up with protein translation company Anima
July 27, 2018 3:36 PM UTC
Eli Lilly and Co. (NYSE:LLY) partnered with Anima Biotech Inc. (Bernardsville, N.J.) to discover and develop translation inhibitors against undisclosed targets chosen by Lilly using Anima's Translation Control Therapeutics platform. Anima and Lilly did not respond to inquiries.
Anima will receive $30 million up front and $14 million in research funding. Anima will also be eligible for $1.1 billion in milestones, plus low to mid single-digit tiered royalties. The pharma will be responsible for clinical development and commercialization...